DPX 103
Alternative Names: DPX-103Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Damona Pharmaceuticals
- Class Small molecules
- Mechanism of Action GABA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 18 Dec 2024 Preclinical in Neurlogical disorders in Canada (unspecified route) (Damona Pharmaceuticals pipeline, December 2024)